These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25116964)

  • 1. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
    İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
    J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
    [No Abstract]   [Full Text] [Related]  

  • 2. Sorafenib-induced annular pustular psoriasis (Milian-Katchoura type).
    Du-Thanh A; Girard C; Pageaux GP; Guillot B; Dereure O
    Eur J Dermatol; 2013; 23(6):900-1. PubMed ID: 24184416
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
    Francini E; Bianco V
    Hepatology; 2014 Aug; 60(2):764-5. PubMed ID: 25187926
    [No Abstract]   [Full Text] [Related]  

  • 4. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
    Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
    Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
    [No Abstract]   [Full Text] [Related]  

  • 5. Grade III hand-foot skin reaction induced by sorafenib.
    Chiriac A; Coros MF; Podoleanu C; Stolnicu S
    An Bras Dermatol; 2017; 92(4):590-591. PubMed ID: 28954127
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
    Shiozawa K; Watanabe M; Ikehara T; Kogame M; Matsui T; Okano N; Kikuchi Y; Nagai H; Ishii K; Makino H; Igarashi Y; Sumino Y
    Hepatogastroenterology; 2014 Jun; 61(132):885-91. PubMed ID: 26158136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
    Xu L; Wang B; Ding W
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e24-e25. PubMed ID: 28163072
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
    Pichard DC; Cardones AR; Chu EY; Dahut WL; Kong HH
    JAMA Dermatol; 2016 Feb; 152(2):227-8. PubMed ID: 26422655
    [No Abstract]   [Full Text] [Related]  

  • 9. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
    Park H; Han SH; Kang H; Park K
    Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
    [No Abstract]   [Full Text] [Related]  

  • 10. Spontaneous deep venous thrombosis: An unrecognized entity with sorafenib.
    Madabhavi I; Patel A; Anand A; Choudhary M; Revannasiddaiah S
    J Cancer Res Ther; 2015; 11(4):1029. PubMed ID: 26881607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib plus cisplatin for hepatocellular carcinoma.
    Brower V
    Lancet Oncol; 2016 Oct; 17(10):e424. PubMed ID: 27617663
    [No Abstract]   [Full Text] [Related]  

  • 12. Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
    Coppola R; Zanframundo S; Rinati MV; Carbotti M; Graziano A; Galati G; De Florio L; Panasiti V
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1028-9. PubMed ID: 24628665
    [No Abstract]   [Full Text] [Related]  

  • 13. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 14. Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
    Chou JW; Cheng KS; Huang CW
    Intern Med; 2016; 55(6):623-7. PubMed ID: 26984079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
    Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
    Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
    Takahashi Y; Fukunishi S; Nishikawa T; Nouda S; Sasaki Y; Sanomura M; Umegaki E; Higuchi K
    Endoscopy; 2013; 45 Suppl 2 UCTN():E179-80. PubMed ID: 23801291
    [No Abstract]   [Full Text] [Related]  

  • 17. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
    Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
    Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
    [No Abstract]   [Full Text] [Related]  

  • 18. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
    Ganten MK; Schuessler M; Bruckner T; Ganten TM; Koschny R
    Oncology; 2015; 89(2):88-94. PubMed ID: 25871578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of intermediate-stage hepatocellular carcinoma.
    Finn RS
    Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.